Studies have demonstrated that ALG3 is overexpressed in oral squamous cell carcinoma (Shao et al., 2021), non–small cell lung cancer (Ke et al., 2020), and breast cancer (Yang et al., 2018; Sun et al., 2021) and contributes to drug resistance in the acute myeloid leukemia (Liu et al., 2020a). Here, ALG3 is linked to breast carcinoma.